The Q-REDUCE Study

Launched by UNIVERSITY OF SOUTHERN DENMARK · Oct 10, 2024

Keywords

ClinConnect Summary

The Q-REDUCE Study is a clinical trial aimed at helping patients who may have dislocated hip prostheses. The main goal of the study is to create a quicker process for treating these patients at the University Hospital of Southern Denmark, Esbjerg. By reducing the time between when a patient arrives at the hospital and when their hip is treated, the researchers hope to also decrease the overall time spent in the hospital. Additionally, they want to find out if faster treatment leads to better hip function and quality of life, less pain both right away and in the long run, and higher patient satisfaction, all while ensuring that the risk of complications or the need for readmission remains the same.

To be eligible for this study, participants should be between the ages of 65 and 74 or 36 and 159, and they must have a history of either total hip arthroplasty (THA) or hip arthroplasty (HA). They should have experienced a sudden movement or twist in their hip that has made it difficult for them to stand or walk. However, individuals who have had multiple dislocations during the same hospital visit, or those with certain health issues that require special monitoring, may not be able to participate. If you join the study, you can expect to receive prompt treatment and to be part of research that could improve care for future patients with similar issues.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • a history of either a THA or a HA in combination with at least one of the following terms
• • having sustained a sudden, incorrect movement or twist in the hip joint in either a bending, sitting or supine position leading to inability to stand or walk
• • misalignment of the concerned lower extremity (typically shortened, with inward/outward rotation)
• Exclusion Criteria:
• • recurrent dislocations during the same hospital admission (already "in the house")
• • anticipated difficult airway by the attending anesthesiologist
• • anticipated need for extended respiratory or hemodynamic monitoring by the attending anesthesiologist
• • American Society of Anesthesiologists (ASA) score \> 3
• • Body Mass Index (BMI) \> 40
• • active drug abuse
• • contraindication for Propofol or Esketamine